Published March 9, 2022
| Version v1
Journal article
Open
Concomitant medication of cetirizine in advanced melanoma could enhance anti-PD 1 efficacy by promoting M1 macrophages polarization
Creators
- Domenico Mallardo1
- Ester Simeone1
- Vito Vanella1
- Maria Grazia Vitale1
- Marco Palla1
- Luigi Scarpato1
- Miriam Paone1
- Teresa De Cristofaro1
- Valentina Borzillo1
- Alessio Cortellini1
- Sandro Pignata1
- Francesco Fiore1
- Corrado Caracò1
- Piera Maiolino1
- Antonella Petrillo1
- Ernesta Cavalcanti1
- Secondo Lastoria1
- Paolo Muto1
- Alfredo Budillon1
- Sarah Warren2
- Paolo Antonio Ascierto1
- 1. Istituto Nazionale Tumori - IRCCS - Fondazione "G. Pascale", Naples, Italy.
- 2. NanoString Technologies, Seattle, USA
Description
Based on the clinical observation of a potential additive effect of anti-PD1 agents and cetirizine in patients with advanced melanoma, the clinical outcomes of concomitant cetirizine/anti-PD1 treatment were evaluated and the possible mechanisms were explored.
Patients treated with cetirizine concomitantly with anti-PD1 agent had significantly longer PFS and OS in comparison with those not receiving cetirizine. The concomitant treatment was significantly associated with ORR and DCR (p<0.05).
Files
Files
(57.1 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:e2c2e2d2219cfe9096c3de5b99d6d853
|
57.1 kB | Download |